India Pharma Outlook Team | Saturday, 19 March 2022
Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India's first mRNA COVID vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources. The firm has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity. Earlier the DG, Indian Council of Medical Research (ICMR) Dr Balram Bhargava informed that this vaccine is going to be useful
in the future for the treatment of other diseases as well and India is heading towards becoming a vaccine superpower. "India is heading towards becoming a vaccine superpower and the fact that these vaccines are going to be available for other diseases," said Dr Bhargava.
Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India's first mRNA COVID vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources. The firm has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity.
Earlier the DG, Indian Council of Medical Research (ICMR) Dr Balram Bhargava informed that this vaccine is going to be useful in the future for the treatment of other diseases as well and India is heading towards becoming a vaccine superpower. "India is heading towards becoming a vaccine superpower and the fact that these vaccines are going to be available for other diseases," said Dr Bhargava.
, CDSCO.jpg)
